ADARx Pharmaceuticals (ADRX) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ADARx Pharmaceuticals is the larger company by market cap ($1.93 billion vs $1.88 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | XERS |
|---|---|---|
| Share price | $18.07 | $10.32 |
| Market cap | $1.93B | $1.88B |
| 1-day change | +2.23% | +1.31% |
| YTD return | — | +29.81% |
| 1-year return | — | +24.27% |
| 5-year return | — | +409.50% |
| Forward P/E | — | 27.90 |
| EPS (TTM) | $-1.16 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | — | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $23.21 | $11.33 |
| 52-week low | $16.64 | $5.25 |
| Distance from 52-week high | -22.15% | -8.89% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +24.57% |
| Average volume | 1.25M | 2.17M |
| Shares outstanding | 106.80M | 182.32M |
| Employees | 100 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
ADRX vs XERS FAQ
Which is bigger, ADARx Pharmaceuticals or Xeris Biopharma?
ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.93B compared with $1.88B for Xeris Biopharma (XERS).
Are ADARx Pharmaceuticals and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.